PMV Pharmaceuticals
PMVP
111 hedge funds and large institutions have $246M invested in PMV Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 44 increasing their positions, 35 reducing their positions, and 17 closing their positions.
63% more call options, than puts
Call options by funds: $161K | Put options by funds: $99K
26% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 35
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
3% less funds holding
Funds holding: 115 → 111 (-4)
6.94% less ownership
Funds ownership: 119.42% → 112.49% (-6.9%)
18% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 17
48% less capital invested
Capital invested by funds: $470M → $246M (-$224M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Verition Fund Management
Greenwich,
Connecticut
|
+$9.68M |
| 2 |
BlackRock
New York
|
+$4.07M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$3.04M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$2.84M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.97M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$17.8M |
| 2 |
RI
RTW Investments
New York
|
-$9.56M |
| 3 |
NI
Nextech Invest
Zurich,
Switzerland
|
-$6.08M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$5.86M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$5.56M |
PMVP Hedge Fund Activity: Q1 2023 in Review
111 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in PMV Pharmaceuticals (PMVP) for Q1 2023, worth a combined $246M — down 48% from $470M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of PMVP and 14 opened new positions — a net loss of 3 holders — while 35 trimmed existing stakes and 44 added.
The largest buyer was Verition Fund Management, adding an estimated $9.68M. The largest seller was State Street, cutting an estimated $17.8M.
- 111 institutional investors held PMV Pharmaceuticals (PMVP) as of Q1 2023, down from 115 in Q4 2022.
- Funds reported $246M of PMV Pharmaceuticals stock for Q1 2023, down 48% quarter-over-quarter.
- 14 funds opened new PMV Pharmaceuticals positions in Q1 2023 and 17 closed out, a net change of -3 holders.
- The largest PMV Pharmaceuticals buyer in Q1 2023 was Verition Fund Management, an estimated $9.68M added.
- The largest PMV Pharmaceuticals seller in Q1 2023 was State Street, an estimated $17.8M sold.
Based on aggregated 13F filings for Q1 2023.